Skip to content
DraconiticResearch
Search Sources API
190,851 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYFrontiers in gastroenterology (Lausanne, Switzerland)

NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C hepatocellular carcinoma and pre-cachexia or cachexia: protocol for a prospective, multicenter, randomized, open-label phase II trial

  • Ruihong Dai1
  • Facheng Lu1
  • Weibing Leng1
  • Qing He1
  • Wenhao Guo1
  • Tao Hai1
  • Chang Liu1
  1. 1Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University , , ,
Read full textPDFCite

Related

  1. MF1, a novel robustic acid derivative, exerts antitumor effects in hepatocellular carcinoma
    Juanjuan Huang, Lijuan Teng, Tianxiu Meng +3
    Translational oncologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  2. Comparative Prognostic Value of AFP, PIVKA-II, and GPC-3 in Hepatocellular Carcinoma: A Real-World Multicenter Cohort Study
    Francesco Damone, Gian Paolo Caviglia, Piero Colombatto +11
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Hepatic arterial infusion chemotherapy plus lenvatinib and programmed death receptor 1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombosis: a prospective controlled study
    Kanglian Zheng, Ming Liu, Xu Zhu +17
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  4. Foundation Model-Enabled Pathology-Informed MRI Model for Preoperative Prediction of Vessels Encapsulating Tumor Clusters in Resectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Zhehan Shen, Wanmin Liu, Xiaoming Li +10
    Advanced science (Weinheim, Baden-Wurttemberg, Germany)Peer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC
  5. Prognostic Significance of Response Dynamics in Atezolizumab plus Bevacizumab-Treated Hepatocellular Carcinoma: A Multicenter Real-World Validation Study.
    Renguo Guan, Kaijun Huang, Zehao Zheng +5
    Liver cancerPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{dai2026plus,
  title = {{NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C hepatocellular carcinoma and pre-cachexia or cachexia: protocol for a prospective, multicenter, randomized, open-label phase II trial}},
  author = {Ruihong Dai and Facheng Lu and Weibing Leng and Qing He and Wenhao Guo and Tao Hai and Chang Liu},
  journal = {Frontiers in gastroenterology (Lausanne, Switzerland)},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13658101},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C hepatocellular carcinoma and pre-cachexia or cachexia: protocol for a prospective, multicenter, randomized, open-label phase II trial
AU  - Ruihong Dai
AU  - Facheng Lu
AU  - Weibing Leng
AU  - Qing He
AU  - Wenhao Guo
AU  - Tao Hai
AU  - Chang Liu
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in gastroenterology (Lausanne, Switzerland)
UR  - https://europepmc.org/article/PMC/PMC13658101
SN  - 2813-1169
ER  -